Enlivex (ENLV) Income from Continuing Operations (2014 - 2025)
Enlivex (ENLV) posted Income from Continuing Operations of -$5.9 million for Q4 2025, down 129.21% on a QoQ basis from -$2.6 million in Q3 2025, and down 4.07% year-over-year from -$6.1 million in Q4 2024.
Analysis
Enlivex (ENLV) Income from Continuing Operations (2014 - 2025) Analysis & Trends
Enlivex has reported Income from Continuing Operations for 12 years, with the latest figure at -$5.9 million in Q4 2025.
- On a quarterly basis, Income from Continuing Operations fell 4.07% year-over-year to -$5.9 million in Q4 2025; TTM through Dec 2025 was -$15.0 million, a 5.41% increase from a year earlier, with the FY2025 full-year figure at $1.2 billion, up 10787.03% from the prior year.
- Income from Continuing Operations was -$5.9 million for Q4 2025 at Enlivex, down from -$2.6 million in the prior quarter.
- The five-year high for Income from Continuing Operations was $2.1 million in Q2 2021, with the low at -$10.3 million in Q4 2023.
- Average Income from Continuing Operations over 5 years is -$4.7 million, with a median of -$5.6 million recorded in 2023.
- The sharpest annual moves came in 2021 and 2022: Income from Continuing Operations surged 277.53% in 2021, then slumped 762.43% in 2022.
- Over 5 years, Income from Continuing Operations stood at -$7.8 million in 2021, then decreased by 0.4% to -$7.8 million in 2022, then sank by 31.74% to -$10.3 million in 2023, then soared by 45.51% to -$5.6 million in 2024, then fell by 4.07% to -$5.9 million in 2025.
- The last three Income from Continuing Operations figures came in at -$5.9 million (Q4 2025), -$2.6 million (Q3 2025), and -$3.1 million (Q2 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 601.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -290.61 Mn |
| 10 | Enlivex | 3.17 Mn | -2.59 Mn | - | -5.86 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | -5.86 Mn |
| Sep 30, 2025 | -2.56 Mn |
| Jun 30, 2025 | -3.08 Mn |
| Mar 31, 2025 | -3.53 Mn |
| Dec 31, 2024 | -5.63 Mn |
| Sep 30, 2024 | -3.12 Mn |
| Jun 30, 2024 | -2.99 Mn |
| Mar 31, 2024 | -4.15 Mn |
| Dec 31, 2023 | -10.34 Mn |
| Sep 30, 2023 | -5.63 Mn |
| Jun 30, 2023 | -6.65 Mn |
| Mar 31, 2023 | -6.78 Mn |
| Dec 31, 2022 | -7.85 Mn |
| Sep 30, 2022 | -5.68 Mn |
| Jun 30, 2022 | -5.87 Mn |
| Mar 31, 2022 | -6.40 Mn |
| Dec 31, 2021 | -7.81 Mn |
| Sep 30, 2021 | 857,000.00 |
| Jun 30, 2021 | 2.06 Mn |
| Mar 31, 2021 | -2.79 Mn |